Related Experiment Video
Updated: Aug 29, 2025
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Challenges for Triple Negative Breast Cancer Treatment: Defeating Heterogeneity and Cancer Stemness
Rinad Mahmoud1,2, Paloma Ordóñez-Morán1,2, Cinzia Allegrucci1,3,4
1Centre for Cancer Sciences, Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK.
Abstract:
The Triple Negative Breast Cancer (TNBC) subtype is known to have a more aggressive clinical course compared to other breast cancer subtypes. Targeted therapies for this type of breast cancer are limited and patients are mostly treated with conventional chemo- and radio-therapies which are not specific and do not target resistant cells. Therefore, one of the major clinical challenges is to find compounds that target the drug-resistant cell populations which are responsible for reforming secondary tumours. The molecular profiling of the different TNBC subtypes holds a promise for better defining these resistant cells specific to each tumour. To this end, a better understanding of TNBC heterogeneity and cancer stemness is required, and extensive genomic analysis can help to understand the disease complexity and distinguish new molecular drivers that can be targeted in the clinics. The use of persister cancer cell-targeting therapies combined with other therapies may provide a big advance to improve TNBC patients' survival.
Insights
Triple Negative Breast Cancer (TNBC) is aggressive with limited targeted therapies. Understanding TNBC heterogeneity and targeting resistant cancer stem cells is crucial for developing new treatments to improve patient survival.
Area of Science:
- Oncology
- Genomics
- Cancer Biology
Background:
- Triple Negative Breast Cancer (TNBC) exhibits aggressive behavior and limited targeted therapy options.
- Current treatments like chemotherapy and radiotherapy lack specificity and fail to address drug-resistant cells.
- Drug-resistant cells are responsible for tumor recurrence and pose a significant clinical challenge.
Purpose of the Study:
- To explore the molecular profiling of TNBC subtypes to identify specific resistant cell populations.
- To enhance the understanding of TNBC heterogeneity and cancer stemness.
- To identify novel molecular targets for improved clinical therapies.
Main Methods:
- Extensive genomic analysis of TNBC subtypes.
- Molecular profiling to distinguish resistant cell populations.
- Investigation of cancer stemness characteristics within TNBC.
Main Results:
- Identified the need for better understanding of TNBC heterogeneity.
- Highlighted the role of molecular profiling in defining resistant cells.
- Emphasized the potential of targeting drug-resistant and cancer stem cells.
Conclusions:
- Targeting drug-resistant persister cancer cells, potentially through combined therapies, may significantly improve outcomes for TNBC patients.
- Further genomic analysis is essential for uncovering new therapeutic targets in TNBC.
- Addressing TNBC heterogeneity is key to developing more effective treatment strategies.
Related Concept Videos
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
02:56Treatment Resistant Cancers
02:18Cancer
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...